Dear Editor,
The article by Kurtoğlu S et al. in the current issue of Turkish Archives of Pediatrics made for an interesting read (1) . In an excellent and timely review, the authors provided a detailed description of symptomatology as well as the effective treatment strategies for fetal and neonatal hyperthyroidism (1) . However, we wish to bring out a missing point in the review related to an uncommon complication that may occur during the treatment of neonatal Graves' disease. The treating physician needs be cautious of this life-threatening complication, which may occur after initiating antithyroid drugs in the neonate.
The hyperthyroid state is associated with bone demineralization resulting in decreased bone mineral density. Severe cases may present with osteoporosis and pathologic fractures (2) . The initiation of anti-thyroid drugs may lead to excessive bone remineralization resulting in hungry bone syndrome (HBS), characterized by hypocalcemia, hypophosphatemia, and hypomagnesemia (3). Severe hypocalcemia due to HBS may manifest as laryngospasm, tetany, and cardiac dysfunction (3, 4) . This condition is relatively common in adults and may occur within hours to months following medical or surgical therapy of hyperthyroidism (3, 6) . Its occurrence in children is rare, probably because a long untreated hyperthyroid state is unusual in children due to early recognition owing to the presence of certain symptoms such as height acceleration, and more commonly associated ophthalmopathy as compared with adults. In infants, hyperthyroidism is often transient and may not have produced much demineralization before initiation of therapy.
An early recognition of HBS following anti-thyroid therapy and prompt institution of therapy is crucial for a successful outcome (3, 4) . For acute management, highdose calcium infusion is given until serum calcium normalizes and symptoms resolve (4, 5) . Oral mineral supplementation may have to be continued for prolonged periods in some cases (5).
In conclusion, while treating a neonate with Graves' disease, the physician should remain alert to the occurrence of HBS after starting anti-thyroid drugs for a timely recognition and management of life-threatening hypocalcemia.
